The big drug industry trade groups PhRMA and BIO are still on track to spend a record amount this year lobbying the federal government — even though neither took a position on the unsuccessful Republican efforts to repeal the Affordable Care Act, the summer’s most hotly contested pieces of legislation.

The two groups have collectively spent more than $26 million lobbying Congress and the executive branch in the first nine months of this year, the most since at least 2008, when organizations began to report their quarterly lobbying spending. By comparison, during the eight years of the Obama administration, the two trade groups collectively spent an average of $21 million on lobbying in the first nine months of the year.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy